MedTrace Logo

Black Bean (Phaseolus Vulgaris L.) Protein Hydrolysates Reduce Acute Postprandial Glucose Levels

NCT05869344 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-05-22

No results posted yet for this study

Summary

This work aimed to evaluate the acute effect of a black bean protein hydrolysate (BPH) on glucose levels in adults with normal glucose tolerance (NGT) and prediabetes. Twenty peptides were identified in BPH, and a followed in silico predictive digestion showed a release of several short-chain peptides with potential hypoglycemic potential. A double-blind, placebo-controlled, randomized clinical trial was conducted on 28 adults with NGT or prediabetes. After consent, participants were randomized into two groups, placebo or the corresponding 5 g BPH treatment. An oral glucose tolerance test (OGTT) (75 g glucose) was used to measure glucose tolerance before treatment. A second OGTT was used to evaluate the acute effect of the BPH, and blood samples were collected at 0, 60, 120, and 150 min, and blood glucose levels were measured.

Conditions

Interventions

DIETARY_SUPPLEMENT

Black bean protein hydrolysates (BPH)

Participants were blinded to treatment and received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of BPH.

OTHER

Commercial non-caloric beverage

Participants were blinded to treatment and received 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of placebo.

Sponsors & Collaborators

  • Claudia Luévano-Contreras

    lead OTHER

Principal Investigators

  • Claudia Luevano Contreras, PhD · Universidad de Guanajuato

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-15
Primary Completion
2019-12-01
Completion
2022-01-21

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05869344 on ClinicalTrials.gov